SAB Biotherapeutics
SABS
SAB Biotherapeutics (SABS) news
Recent news
SAB Biotherapeutics slides 7% premarket after announcing 1-for-10 reverse stock split
SAB Biotherapeutics slides 7% premarket after announcing 1-for-10 reverse stock split SAB Biotherapeutics, a clinical-stage biopharmaceutical company, announced on January 2, 2024, that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, effective…
AInvest Wire · Jan 3, 2024SAB Biotherapeutics jumps 17% after receiving Australian approval to commence Phase 1 clinical trial of SAB-142
AInvest Wire · Oct 19, 2023SAB Biotherapeutics receives Australian approval to commence Phase 1 clinical trial of SAB-142
AInvest Wire · Oct 19, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.